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SLC10A7 mutations cause a skeletal dysplasia with
amelogenesis imperfecta mediated by GAG
biosynthesis defects
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Skeletal dysplasia with multiple dislocations are severe disorders characterized by disloca-
tions of large joints and short stature. The majority of them have been linked to pathogenic
variants in genes encoding glycosyltransferases, sulfotransferases or epimerases required for
glycosaminoglycan synthesis. Using exome sequencing, we identify homozygous mutations
in SLC10A7 in six individuals with skeletal dysplasia with multiple dislocations and amelo-
genesis imperfecta. SLC10A7 encodes a 10-transmembrane-domain transporter located at the
plasma membrane. Functional studies in vitro demonstrate that SLC10A7 mutations reduce
SLC10A7 protein expression. We generate a Slc10a7−/− mouse model, which displays
shortened long bones, growth plate disorganization and tooth enamel anomalies, recapitu-
lating the human phenotype. Furthermore, we identify decreased heparan sulfate levels in
Slc10a7−/− mouse cartilage and patient ﬁbroblasts. Finally, we ﬁnd an abnormal N-glyco-
protein electrophoretic proﬁle in patient blood samples. Together, our ﬁndings support the
involvement of SLC10A7 in glycosaminoglycan synthesis and speciﬁcally in skeletal
development.
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Skeletal dysplasias with multiple dislocations are a group ofsevere disorders characterized by dislocations of large joints,scoliosis, short stature and a variable combination of cleft
palate, heart defects, intellectual disability and obesity1,2. More
than 10 recessive disorders, including Desbuquois dysplasia and
Larsen of Reunion Island syndrome have been described so far3–
5. With the help of massively parallel sequencing technologies, the
majority of these rare disorders have been linked to pathogenic
variants in genes encoding glycosyltransferases (“linkeropathies”)
6,7, sulfotransferases8,9, epimerases10 or transporters11, required
for glycosaminoglycan (GAG) biosynthesis12. These ﬁndings
support the existence of a group of inborn errors of development
deﬁned by impaired GAG biosynthesis. Pathogenic variants in
genes encoding proteins with no known functions have also been
implicated in impaired proteoglycan synthesis; e.g., ﬁbroblasts
from patients with pathogenic variants of calcium-activated
nucleotidase-14 display defective proteoglycan synthesis13. These
ﬁndings suggest that GAG synthesis is more complex than pre-
viously described and suggests that there are a number of partners
of unknown function still to be identiﬁed.
In this study, exome sequencing is performed on a number of
patients presenting with skeletal dysplasia with multiple disloca-
tions, identifying six cases of homozygous mutations in SLC10A7.
This gene encodes a member of the Solute Carrier Family SLC10,
which comprises two bile acid carriers, one steroid sulfate
transporter and four orphan carriers. SLC10A7 is a 10-
transmembrane-domain transporter located at the plasma
membrane, with a yet unidentiﬁed substrate14. Using a deﬁcient
mouse model and patient ﬁbroblasts, we demonstrate that
SLC10A7 deﬁciency disrupts GAG biosynthesis and intracellular
calcium homoeostasis.
Together, our ﬁndings support the involvement of SLC10A7 in
GAG biosynthesis and speciﬁcally in skeletal and tooth
development.
Results
Phenotypes of patients with SLC10A7 mutations. The six
patients were from six distinct families, originating from Turkey
(three patients, consanguineous parents), from the Netherlands
(two patients) and from Iran (one patient, consanguineous par-
ents). They presented with pre- and postnatal short stature
(<−3 SD), dislocation of large joints, advanced carpal ossiﬁcation,
monkey wrench appearance of the proximal femora in the ﬁrst
months of life, abnormal vertebrae, luxation of knees with genua
valga, hyperlordosis or kyphoscoliosis and small epiphyses
(Table 1 and Fig. 1). In addition, hypomineralized amelogenesis
imperfecta, characterized by yellow–brown enamel with a rough
surface, and short and widely spaced tooth crowns, was diagnosed
in all six patients (Table 1). Facial abnormalities were present in all
patients: a Pierre–Robin sequence (micrognathia, cleft palate and
glossoptosis) in two patients, a micrognathia in three other cases
and a ﬂat face in the last patient. Additional features observed
included a heart defect (one patient), mixed (one patient) and
sensorineural hearing loss (one patient), and obesity in the eldest
patients. The parents of the Iranian patient have a history of
multiple pregnancies that resulted in a spontaneous abortion and
neonatal death due to respiratory distress accompanied by
micromelia. Two other pregnancies were terminated preterm after
the detection of short limbs during ultrasound screening. One of
these induced abortions presented an additional cleft palate.
SLC10A7 mutations and functional analysis. A total of ﬁve
distinct homozygous SLC10A7 (GenBank: NM_001317816)
mutations were identiﬁed (Fig. 1h and Supplementary Fig. 1a).
Two were splice site mutations, located in the acceptor site of
exon 10 (c.774-1 G > A) and in the donor site of exon 9 (c.773+
1 G > A), two mutations were a missense substitution located in
exon 3 (c.221 T > C [p.Leu74Pro]) and exon 4 (c.388 G > A [p.
Gly130Arg]), which were predicted to be damaging by the
PolyPhen and Sift algorithms, and one inserted a premature stop
codon into exon 7 (c.514 C > T [p.Gln172*]). The two Dutch
patients that carried this mutation were genealogically proven to
be distantly related through their fathers, while it was not possible
to prove a genealogical link between their mothers (Supplemen-
tary Fig. 1b). All mutations segregated with the disease (Supple-
mentary Fig. 1b) and were not identiﬁed in 200 control
chromosomes or public databases.
SLC10A7 encodes a 10-transmembrane-domain transporter
located at the plasma membrane. Three of the mutations are
predicted to be null alleles (affecting essential splice sites or
generating a premature stop), whereas the missense variant p.
Leu74Pro affects a highly conserved amino acid in the third
predicted transmembrane helix. The second missense variant, p.
Gly130Arg, also affects a highly conserved amino acid, albeit not
residing within a known protein domain. Analyses of comple-
mentary DNA from patients carrying SLC10A7 mutations
affecting splice sites identiﬁed exon 9 skipping for the c.773+
1 G > A mutant and an exon 10, and exon 9 and 10 skipping for
the c.774-1 G > A mutant. Exon 9 and 10 skipping led to an in-
frame deletion of 42 amino acids (Supplementary Fig. 2). We
tested the functional consequences of SLC10A7 mutations using
c-myc-tagged wild-type and mutant SLC10A7 (c.774-1 G > A and
p.Leu74Pro) in parallel transfections of HEK293F cells. C-myc
tagged protein expression was analysed 48 h after transfection. C-
myc immunolabelling demonstrated a uniform punctate staining
following transfection with wild-type SLC10A7, consistent with a
cell membrane localization. A similar expression pattern was
observed for all SLC10A7 mutants; however, the level of staining
was reduced with the weakest staining being observed with the p.
Leu74Pro mutant (Fig. 2a). Similar results were obtained
following transfection of COS-1 and MG63 cells (Supplementary
Fig. 1b). To conﬁrm the altered expression pattern detected with
the SLC10A7 mutants, total HEK293F cell lysates were analysed
by western blotting. A signiﬁcant reduction in the expression of
the SLC10A7 mutants compared with wild-type was observed
(Fig. 2b). Together, these results demonstrate the deleterious
impact of the identiﬁed mutations on SLC10A7 protein
expression.
SLC10A7 is expressed in developing skeletal tissues. To corre-
late the spatio-temporal expression pattern of SLC10A7 with
patient manifestations, in situ hybridization experiments were
performed on embryonic and juvenile mouse tissues, i.e., from
gestational age 12.5 days (E12.5) to postnatal day 10 (P10).
Slc10a7 mRNA was detected at all the developmental stages
studied (Supplementary Fig. 3b), generally localizing to cartilage
giving rise to long bones in embryos and in the growth plates of
long bones in juvenile mice (Fig. 2c). E12.5 embryos showed the
weakest expression, mainly in the heart trabeculae of the devel-
oping heart and the cartilage of the vertebrae (Supplementary
Fig. 3b). From E14.5 onwards, Slc10a7 mRNA expression became
more ubiquitous, with the strongest expression observed at E16.5
and P0. At E14.5, Slc10a7 mRNA was strongly expressed in
cartilaginous structures such as in the mandible (i.e., Meckel
cartilage), in the digits, in the spine and in the lung (Fig. 2c). At
P10, Slc10a7 mRNA expression was localized to the growth plate
of several long bones, such as the forefoot digits, the hindfoot
tarsals and the humerus, and was more intense in the chon-
drocytes of the hypertrophic zone. Interestingly, at P0 there was
stronger expression in the papillary layer of the oral mucous
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Table 1 Clinical features of the six cases
Family 1 Family 2 Family 3
A. Ethnic origin
B. Consanguinity
A. Turkish
B. First cousins
A. Turkish
B. First cousins
A. Turkish
B. Related parents
Parameters and clinical
exam at birth
• Term
• Length: 44 cm
•Weight: 3600 g
• Term
• Length: 48 cm
•Weight: 1945 g
•Head circumference: 33 cm
•Hypermobile large joints
• Respiratory distress
• Term
• Length: 44 cm
•Weight: 3106 g
• Pierre–Robin sequence
• Transient respiratory distress
Clinical features at ﬁrst
exam
At 3 years of age:
• Short stature
• Short extremities
• Round face
•Microretrognathia
•Hypermobile joints
At 6 months of age:
• Length <−3 SD
• Round face
•Depressed nasal bridge
•High palate
•Micrognathia
•Hypermobile joints
At 3 years of age:
• Parameters < P3
•Hypermobile joints
•Microretrognathia
Radiological features •Advanced bone age
• Proximal femur “Swedish key”
• Short metacarpals and phalanges
• Irregular vertebral bodies
•Wide metaphyses
• Coxa valga
•Advanced carpal ossiﬁcation
• Proximal femur “Swedish key”
• Irregular vertebral bodies
•Advanced carpal bone age
• Proximal femur “Swedish key”
• Small epiphyses
Follow-up: growth and
skeleton
5 years:
•Height <−3 SD
• Knee dislocation
•Hyperlordosis
•Obesity
2 years:
•Height <−3 SD
• Knee dislocation
• Small epiphyses
4 years:
•Height <−5.8 SD
•Hyperlordosis
• Truncal obesity
Other •Amelogenesis imperfecta
• Tooth agenesis (22 teeth at 13 years
of age)
•Amelogenesis imperfecta
•Atrial septal defect
•Amelogenesis imperfecta
• Speech delay ( >3 years)
Family 4 Family 5 Family 6
A. Ethnic origin
B. Consanguinity
A. Dutch A. Dutch A. Iranian
B. First cousins
Parameters and clinical
exam at birth
• Term
• Length: 40.3 cm
•Weight: 3530 g
•Head circumference: 36 cm
• Flat face, short thorax, short
extremities
• 39+ 3
• Length: 42.5 cm
•Weight: 2680 g
• Pierre–Robin sequence respiratory
insufﬁciency (8 days intubation)
• Term
• Short extremities
• Respiratory distress (ventilator for 1
day)
Clinical features at ﬁrst
exam
At 6 months of age:
•Disproportionate short stature,
height <−5 SD
• Extreme hypermobile knees in
hyperextension
8 months:
•Disproportionate short stature −3 SD
•Genu valgum
Radiological features •Advanced carpal and tarsal
ossiﬁcation
• Butterﬂy vertebrae Th11, Th12,
horizontal acetabular roof
•Advanced carpal ossiﬁcation
• Proximal femur “Swedish key”
• Irregular vertebral bodies and coronal
clefts
•Advanced carpal ossiﬁcation
• Short metacarpals (especially of the
4th and 5th ﬁnger)
Follow-up: growth and
skeleton
10 years:
•Height −5 SD
• Knee dislocation in extreme valgus
• Severe kyphoscoliosis and
hyperlordosis
• Contractures of the hip
• Sitting height −2.3 SD
•OFC 1.87 SD
9 years:
•Height: −4.8 SD
•Genu valgum
• Small epiphyses
• Kyphoscoliosis
•Hypermobility
At 11 years of age:
•Height <−4 SD
•Genu valgum
• Short extremities
•Micrognathia
•Hyperlordosis
• Patellar instability on the right
• Truncal obesity
Other •Amelogenesis imperfecta •Amelogenesis imperfecta
• Tooth agenesis (Missing teeth: 14 15 24
25 35 44 45)
•Mixed hearing loss
•Amelogenesis imperfecta
• Tooth agenesis (7 teeth at 12 years
of age)
• Sensorineural hearing impairment
•Decreased visual acuity
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membrane underneath the palate, as well as in the ameloblast
layer of emerging teeth.
To investigate whether the expression patterns observed in
mice are also seen in humans, the same experiments were
performed on human embryos at 8 and 9 weeks of gestation
(Carnegie stages 16 and 19). Similar expression patterns were
observed: SLC10A7 mRNA was detected in the heart and the
vertebrae at 8 weeks and in the long-bone cartilage at 9 weeks
(Supplementary Fig. 3c).
Slc10a7 deﬁciency causes skeletal dysplasia in mice. In order to
decipher the impact of Slc10a7 deﬁciency on bone development
in vivo, a Slc10a7-deﬁcient mouse strain was generated using
embryonic stem (ES) cell lines from European Mouse Mutant
Cell Repository (EuMMCR) in which a lacZ/neo cassette was
inserted into intron 1 of Slc10a7 gene: the resulting heterozygous
mice (Slc10a7+/−) were intercrossed to obtain homozygous mice
(Slc10a7−/−). At birth, Slc10a7−/− mice were smaller, displaying
signiﬁcantly reduced body weight (1.121 g ± 0.02188 [Slc10a7−/−]
vs. (1.297 g ± 0.03913 [Slc10a7+/+]), reduced naso-occipital
length and a more rounded head (as observed with X-ray ima-
ging) compared with wild-type littermates (Fig. 3a). Morpho-
metric measurements indicated that the stylopod (femur and
humerus) and zeugopod (tibia and radius) were more affected
than the autopod (hindfoot and forefoot) (Supplementary
Fig. 4a). Although Slc10a7−/− hindfeet were smaller, the
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Fig. 1Morphological and skeletal features of SLC10A7-deﬁcient patients. a Skull X-ray at 6 years of age (Patient 5). Note the retrognathia (arrow). b Hip at
one year of age (Patient 1). Note the Swedish key appearance of the proximal femur (medial beak and exaggerated trochanters, arrow). c Hand X-rays at
6 months of age (Patient 2). d Hand X-rays at 3 years of age (Patient 3). Note in (c) and (d, the advanced carpal ossiﬁcation (presence of three ossiﬁed
carpal centres at 6 months and seven ossiﬁed carpal centres at 3 years instead of one and three, respectively, see arrows). e Knee at 3 years 9 months of
age (Patient 3). Note the genu valgum (angled in knee) and ﬂat epiphyses (arrow). f Spine X-rays at 1 month of age (Patient 1). Note the coronal clefts and
irregular shape of vertebrae (arrow). g Spine and hip X-rays at 9 years of age (Patient 4). Note the kyphoscoliosis. Informed consent for publication of
images was obtained from all individuals or the legal guardians of minors. h Localization of the ﬁve SLC10A7 mutations relative to the SLC10A7 gene
organization (striped rectangles indicate the 5′ and 3′-UTRs)
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05191-8
4 NATURE COMMUNICATIONS |  (2018) 9:3087 | DOI: 10.1038/s41467-018-05191-8 | www.nature.com/naturecommunications
proportion of ossiﬁed tissue, visualized using alizarin red staining,
was greater in the tarsals, metatarsals and phalanges of Slc10a7
−/− mice compared with wild-type littermates, suggesting
advanced ossiﬁcation (Supplementary Fig. 4c). The growth delay
of Slc10a7−/−mice continued after birth and at 8 weeks they were
smaller than their wild-type littermates (Fig. 3b, c). However, the
differences in size reduction between the stylopod/zeugopod and
autopod of the Slc10a7−/− mice was less pronounced than at
birth (Supplementary Fig. 4b). No obvious large joint dislocations
were visible on the x-rays of Slc10a7−/− mice at birth or at
8 weeks of age. Skull morphology alterations at 8 weeks was
analysed by micro-computed tomography (μCT) analyses. The
length and width and the overall elongation (determined from the
length/width ratio) of the Slc10a7−/− skulls was reduced com-
pared with wild-type littermates (Fig. 3d). More precise mea-
surements demonstrated that mostly nasal bone, frontal bone and
occipital bone lengths were reduced, while parietal bone length
was less reduced and interparietal bone length was not affected in
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Fig. 2 SLC10A7 mutation consequences and Slc10a7 tissular expression. a, b Characterization of wild-type and mutant SLC10A7 proteins. HEK293F cells
were transfected with plasmids encoding c-myc tagged wild-type SLC10A7 proteins or c-myc-tagged mutant SLC10A7 proteins from two different patients
(Patient 1 and Patient 3). a Cells were immunostained with anti-c-Myc antibody (red) and nuclei were counterstained with DAPI (blue). Scale bars= 20
μm. The images are representative of three independent experiments. b Total cell lysates were analysed by western blotting using c-Myc antibody. Anti-
actin was used as a loading control. The western blot images are cropped from gels that were provided for review as Supplementary Fig. 1d. c In situ
hybridization analysis of Slc10a7 mRNA expression in E14.5 mouse embryos and P10 mouse tissues. The blue staining indicates sites of RNA hybridization.
At E14.5, empty arrows indicate speciﬁc staining in cartilaginous tissues: Meckel cartilage (left panel) in the mandible and phalanges in the digits (central
panel) and vertebrae (right panel). Note the positive staining in the lung on the right panel. At P10, ﬁlled arrows indicate speciﬁc staining in the
hypertrophic zone of the growth plate in the digits (left panel), in the tarsals (central panel) and in the epiphysis of the humerus (right panel). Scale bars=
250 μm
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Fig. 3 Slc10a7−/− mice display skeletal dysplasia with skull anomalies. a, b Measurement of body weight and naso-occipital length (body length) and
radiographic assessment of Slc10a7+/+, Slc10a7+/− and Slc10a7−/− mice at birth (a) or at 8 weeks (b), demonstrating that Slc10a7−/− mice exhibited a
skeletal dysplasia with a more rounded skull. c Evolution of body weight demonstrating the growth delay in Slc10a7−/− mice compared with wild-type
littermates. d Three-dimensional reconstruction of 8-week-old mouse skulls by μCT analysis and skull length and width measurements, demonstrating that
Slc10a7−/− skulls are less elongated than wild-type skulls. Scale bars= 5mm. Data are expressed as mean ± SD. NS, nonsigniﬁcant; ***p≤ 0.001;
****p≤ 0.0001 (two-tailed t-test). n= 13 (Slc10a7+/+), n= 35 (Slc10a7+/−) and n= 19 (Slc10a7−/−) at birth; n= 7 (Slc10a7+/+), n= 7 (Slc10a7+/−) and
n= 6 (Slc10a7−/−) at 8 weeks
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Slc10a7−/− skulls. Furthermore, only parietal bone and occipital
bone widths were slightly smaller in Slc10a7−/− skulls compared
to wild-type skulls (Supplementary Fig. 5a). This affected the
mandible morphology as the angle formed by the two hemi-
mandibles was signiﬁcantly increased in Slc10a7−/− mice com-
pared with wild-type littermates (Supplementary Fig. 5b). Out of
six analysed Slc10a7−/− mice, two presented with a deviated nasal
bone (Supplementary Fig. 5c) and one with a shortened nasal
bone, whereas no nasal bone abnormalities were observed in
Slc10a7+/− and Slc10a7+/+ mice, suggesting an incomplete
penetrance for that phenotype. No signiﬁcant differences were
observed in any morphometric measurements performed com-
paring Slc10a7+/− and Slc10a7+/+ mice.
SLC10A7 deﬁciency leads to craniofacial and tooth anomalies.
As described earlier, all six patients were diagnosed with hypo-
mineralized amelogenesis imperfecta. More precisely, intra-oral
examination revealed yellow–brown enamel with a rough surface.
Tooth crowns were short and widely spaced giving the appear-
ance of mild microdontia. The enamel layer could not be dis-
tinguished on the panoramic radiography, indicating
hypomineralization of enamel (Fig. 4a) and tooth agenesis was
observed. To determine whether Slc10a7 deﬁciency also results in
tooth defects in mice, mandibles and teeth of Slc10a7−/− mice
were analysed. Three-dimensional analyses of mouse heads
revealed a decrease in volume of all anatomical structures
(mandible, molars and incisors) in the same proportion (Fig. 4b).
Mature enamel from the incisors was analysed by scanning
electronic microscopy. Enamel thickness was not proportionally
decreased in Slc10a7−/− mice compared with wild-type litter-
mates as the ratio of enamel thickness to incisor thickness was
similar in Slc10a7−/− mice and wild-type littermates, and incisor
morphology was conserved (Supplementary Fig. 6). In wild-type
mice, enamel consists of three layers: aprismatic (without enamel
rods), external prismatic (all prisms are cut transversally) and
internal prismatic (prisms are alternatively cut in sagittal and
transverse orientation). In the Slc10a7−/− mouse incisors, the
most external layer, the aprismatic enamel layer, was missing
(Fig. 4c). Furthermore, numerous areas of hypoplasia were
observed in the external prismatic enamel layer of Slc10a7−/−
mice (Fig. 4c). High magniﬁcation of the prismatic enamel layer
in Slc10a7−/− mice revealed less well-deﬁned rods and inter-rod
structures compared with wild-type mice (Fig. 4c).
Slc10a7 deﬁciency alters long-bone microarchitecture. Both at
birth and at 8 weeks, long bones of Slc10a7−/− mice were shorter
and thicker than wild-type mouse bones, as demonstrated by the
reduced length/width ratio (Fig. 5a, b). At 8 weeks, Slc10a7−/−
femurs exhibited enlarged distal condyles, more prominent
proximal trochanters and shorter necks, giving the speciﬁc
“Swedish key” aspect to the proximal femur observed on the X-
rays of SLC10A7-deﬁcient patients (Fig. 5b). To examine whether
the morphological alterations of Slc10a7−/− mouse femurs were
associated with microstructural bone defects, μCT analyses were
performed on femur distal condyles from 8-week-old mice.
Morphological defects were detected in the three-dimensional
reconstructions of femur metaphysis sections of Slc10a7−/− mice,
where a triangular shape instead of the elliptic shape seen in wild-
type bones was observed (Fig. 5c). Quantitative analyses revealed
that Slc10a7−/− mice have a signiﬁcantly lower bone volume/total
volume ratio, both for trabecular bone and cortical bones com-
pared with wild-type littermates (Fig. 5c). Trabecular thickness
(Tb.Th.) but not trabecular number (Tb.N.) was signiﬁcantly
reduced (Tb.Th.: 0.0525 mm ± 0.0053 [Slc10a7+/+] vs. 0.0399
mm ± 0.0021 [Slc10a7−/−], p < 0.001; Tb.N.: 3.76 mm−1 ± 0.825
[Slc10a7+/+] vs. 3.14 mm−1 ± 0.526 [Slc10a7−/−], p= 0.13), and
bone mineral density was signiﬁcantly decreased in trabecular but
not cortical bone of Slc10a7−/− mice compared with wild-type
littermates (Fig. 5c).
Safranin O staining of histological sections from newborn distal
femurs demonstrated a reduction in the size of epiphyses in
Slc10a7−/− mice compared with wild-type mice. There was a
strong reduction of Safranin O staining, a marker of sulfated GAG
chains, in Slc10a7−/− mice compared with wild-type mice, which
was associated with disorganization of the growth plate (Fig. 5d).
This disorganization was more visible when histological sections
were stained with Masson’s Trichrome. Overall, the Slc10a7−/−
growth plates were much thinner than wild-type growth plates.
The different chondrocyte layers, i.e., resting, proliferative,
prehypertrophic and hypertrophic zones, were less discernible in
Slc10a7−/−mice compared with the wild-type littermates (Fig. 5e).
The columnar organization of proliferative chondrocytes was
visible; however, proliferative chondrocytes were more tightly
packed and the thickness of the proliferative zone was reduced in
Slc10a7−/− mice. The prehypertrophic/hypertrophic zone was the
most affected layer in Slc10a7−/− growth plates, the thickness of
the hypertrophic zone in Slc10a7−/− mice was limited to two to
three cells with anarchic alignment. Interestingly, a denser blue
staining (corresponding to collagen ﬁbres) was observed in the
growth plates of Slc10a7−/− mice compared with wild type.
Together, these results suggest an alteration in the composition of
extracellular matrix, possibly due to a reduced proteoglycan/
collagen ratio leading to growth plate disorganization and bone
growth delay.
SLC10A7 deﬁciency leads to GAG biosynthesis defect. To
conﬁrm the histological analyses suggesting a proteoglycan deﬁ-
ciency in Slc10a7−/− growth plates, GAG content from SLC10A7-
deﬁcient patient ﬁbroblasts and in cartilage extracts from 10-day-
old Slc10a7−/− mice was measured. Although no signiﬁcant dif-
ference in total GAG was detected in either sample compared
with controls (Fig. 6a, b), the proportion of heparan sulfate (HS)
was signiﬁcantly reduced by ~2-fold in SLC10A7-deﬁcient patient
ﬁbroblasts compared with control ﬁbroblasts and by about 2.5-
fold in Slc10a7−/− mouse cartilage compared with wild-type
mouse cartilage (Fig. 6a, b). Interestingly, no signiﬁcant difference
was evident in the proportion of HS in muscle (measured as a
control tissue), between Slc10a7−/− mice and Slc10a7+/+ mice
(Supplementary Fig. 7a). To investigate whether the HS from
Slc10a7−/− mouse cartilage were altered in their sulfation part-
ners, we digested them with a heparitinase cocktail to generate
HS-derived sulfated disaccharides that could reﬂect altered sul-
fotransferases activities. High-performance liquid chromato-
graphy (HPLC) analysis of disaccharides from Slc10a7−/− and
Slc10a7+/+ mice showed no difference in their sulfation patterns
(Supplementary Fig. 7b), indicating non-altered HS sulfo-
transferases activities in the Slc10a7−/− mice. We then examined
the GAGs chain length by gel electrophoresis and, again, non-
difference was detected in HS chain size between Slc10a7−/− and
Slc10a7+/+ mice (Supplementary Fig. 7c), indicating that HS
decrease in Slc10a7−/− is mostly related to the number of HS
chains, rather than to their sulfation and length.
Immunohistoﬂuorescence experiments were used to visualize
HS and chondroitin sulfate (CS) in newborn mouse cartilage.
From birth, the overall intensity of HS immunostaining was
signiﬁcantly reduced in Slc10a7−/− mice compared with wild-
type mice (Fig. 6c). However, the distribution of HS immunos-
taining in Slc10a7−/− cartilage was variable with markedly
reduced HS immunostaining of extracellular matrix being
accompanied by intensely stained chondrocytes. No signiﬁcant
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Fig. 4 SLC10A7 deﬁciency leads to enamel anomalies in human and in mice. a Intra-oral photography of Patient 4 at 9 years of age showing
hypomineralized amelogenesis imperfecta (left panel). X-ray panoramic of Patient 5 at 6 years of age showing absence of enamel radiolucency
corresponding to amelogenesis imperfecta associated with severe oligodontia (right panel). b Three-dimensional reconstruction of mandibles from μCT
analysis of 8-week-old mouse skulls and volume measurement of mandibles, lower incisors and lower molars at 8 weeks. Scale bars= 1 mm. Data are
expressed as mean ± SD. NS, nonsigniﬁcant; ****p≤ 0.0001 (two-tailed t-test). n= 7 (Slc10a7+/+), n= 7 (Slc10a7+/−) and n= 6 (Slc10a7−/−). c Scanning
electron microscopy of mandible incisor from Slc10a7+/+ and Slc10a7−/− mice. Low magniﬁcation (left panels) shows conservation of enamel morphology
but decreased thickness in Slc10a7−/− mice. The boxed areas in the left panels are shown at higher magniﬁcation (middle and right panels). In Slc10a7−/−
mouse enamel, the aprismatic layer was absent and the external prismatic layer was altered giving a rough aspect to the enamel surface (middle panels:
arrows indicate hole in the external prismatic layer; a= aprismatic enamel layer, ep= external prismatic layer, ip= internal prismatic layer). High
magniﬁcation of internal prismatic enamel shows absence of a well-deﬁned prismatic pattern in Slc10a7−/− mice, with fused rods and inter-rod structures
(right panels; r= rod, ir= inter-rod). Scale bars= 20 μm. These images represent three incisors analysed
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difference in CS immunostaining intensity was measured between
Slc10a7−/− growth plates and wild-type controls. However, CS
immunostaining was less homogenous with more intense staining
at close proximity to some chondrocytes in Slc10a7−/− growth
plates compared with wild-type controls (Fig. 6c). These data
provide further evidence that SLC10A7 deﬁciency results in
impaired GAG biosynthesis.
Based on the fact that SLC10A7 yeast orthologs are known to
be putative negative regulators of cytosolic calcium
homoeostasis15,16, free intracellular calcium in SLC10A7-deﬁcient
patient ﬁbroblasts and control ﬁbroblasts was assessed. After
addition of extracellular CaCl2, SLC10A7-deﬁcient patient
ﬁbroblasts showed a signiﬁcantly increased Ca2+ inﬂux compared
with control ﬁbroblasts (Fig. 6d).
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SLC10A7 deﬁciency leads to altered N-glycoprotein pattern.
Finally, the electrophoretic proﬁle of N-glycoproteins, orosomu-
coid, haptoglobin, transferrin and alpha-1-anti-trypsin, was
analysed from dried blood spots obtained from SLC10A7 patients
in order to determine whether these proteins carried N-glycosy-
lation defects. By classical SDS-polyacrylamide gel electrophoresis
(PAGE), orosomucoid and haptoglobin migrated faster in the
patient samples than in the control samples (Supplementary
Fig. 8). Two-dimensional electrophoresis showed a shift of the far
right haptoglobin glycoforms. Together, these results suggest an
impact on remodelling of glycans, resulting in truncated and
abnormal glycan structures.
Discussion
This study presents evidence that homozygous mutations in
SLC10A7 are responsible for skeletal dysplasia and amelogenesis
imperfecta. Five SLC10A7 variants were identiﬁed in four patients
from four unrelated families and two patients from two distantly
related families, segregating according to a recessive mode of
inheritance (Supplementary Fig. 1b). SLC10A7 mutations were
shown to impair SLC10A7 protein synthesis, as evidenced by the
reduced signal detected by immunocytoﬂuorescence and western
blot analyses. Inactivation of Slc10a7 in a mouse model resulted
in a complex phenotype, including abnormal development of
skeletal structures and teeth anomalies that recapitulated the
human phenotype, supporting the conclusion that SLC10A7
mutations are the cause of the clinical phenotype.
Individuals with SLC10A7 mutations presented with severe
pre- and postnatal disproportionate short stature, micro-
retrognathia, dislocations with monkey wrench appearance of the
femora, short long bones with metaphyseal widening and
advanced carpal and tarsal ossiﬁcation. Of particular interest, all
patients were diagnosed with amelogenesis imperfecta, while no
tooth anomalies have been described in the group of skeletal
dysplasias with multiple dislocations2,6,7. Thus, amelogenesis
imperfecta can be considered as a new clinical feature indicative
of SLC10A7 mutations.
SLC10A7, previously named C4orf1317, is a 340-amino acid
10-transmembrane-domain protein localized at the plasma
membrane (conﬁrmed by the immunocytoﬂuorescence assay
performed in this study). It is a member of the SLC10 family that
comprises a Na+/taurocholate co-transporting polypeptide
(SLC10A1) and an apical sodium-dependent bile acid transporter
(SLC10A2). SLC10A7 is an atypical member of this carrier family
both with regards to its genomic organization, membrane
topology and transport function. The SLC10A7 gene is composed
of 12 exons and is present in vertebrates, plants, yeast and bac-
teria14. Its speciﬁc function and substrate remain unknown. For
example, no transport activity was detected for the bile acids
taurocholate, cholate and chenodeoxycholate, and the ster-
oidsulfates estrone-3-sulfate, dehydroepiandrosterone sulfate and
pregnenolone sulfate14. However, two studies performed with
SLC10A7 homologues in yeast, CaRch1p and Rch1p, suggest a
possible role as a negative regulator of cytosolic calcium
homoeostasis15,16. Furthermore, a study on high-throughput
screening of mouse gene knockouts very succinctly described a
moderate skeletal dysplasia associated with loose joints in a
Slc10a7−/− mouse model18
In situ hybridization conﬁrmed the broad expression of Slc10a7
mRNA expression in mouse as previously described14,17.
SLC10A7 mRNA was more speciﬁcally expressed in tissues
affected in patients, i.e., cartilage giving rise to long bones and
long-bone growth plates (skeletal dysplasia), emerging teeth
(amelogenesis imperfecta), lungs and developing heart (con-
genital heart defect in one patient), strengthening the implication
of SLC10A7 deﬁciency in the occurrence of those clinical features.
A Slc10a7-deﬁcient mouse model was generated to further
understand the function of SLC10A7. The choice of a constitutive
knock-out mouse model was coherent with the loss of function
mutations identiﬁed in patients. Even though a Slc10a7−/−
mouse model was previously described18, it only provided a brief
analysis of long bones and joint in adult mouse. Our Slc10a7−/−
mice presented with skeletal dysplasia including growth retarda-
tion at birth and at 8 weeks, alteration of long-bone morphology,
craniofacial anomalies and advanced tarsal maturation at birth,
associated with enamel defects, demonstrating a strong correla-
tion with the human phenotype. However, no obvious joint dis-
location was observed in Slc10a7−/− mice. This may mean that
Slc10a7−/− mice differ from patients and do not have joint
abnormalities. More likely, more subtle joint defects are present
and that joint laxity is only detectable by speciﬁc measurement,19
or joint abnormalities would appear in older mice as loose joints
were described in another Slc10a7−/− mouse model18.
Immunohistoﬂuorescent analyses of newborn mouse growth
plates and GAG quantiﬁcation in patient ﬁbroblasts and in mouse
cartilage all demonstrated an alteration of proteoglycan GAG
moieties synthesis, a phenotype previously described for other
chondrodysplasias with multiple dislocations2,6,7,13. Proteogly-
cans are extracellular matrix macromolecules where GAG chains,
consisting of repeating sulfated disaccharide units, are attached to
a core protein. The cellular functions of these proteoglycans are
fundamental and mainly depend on the composition of the
GAGs. The GAG biosynthesis, initiated at the exit of endoplasmic
reticulum, takes place essentially in the Golgi apparatus20. In the
secretory pathway, normal glycosylation, and thus GAG bio-
synthesis, is highly dependent on a correct Golgi cisternae orga-
nization, with shallow pH gradient and regulated enzymatic and
ionic content12,21. For example, Ca2+concentration has a major
role in that process as calcium depletion from Golgi and endo-
plasmic reticulum lumens induced by thapsigargin affects col-
lagen and proteoglycans synthesis22, and increased extracellular
Ca2+ levels also reduces proteoglycan secretion23,24. In this study,
SLC10A7 deﬁciency was demonstrated to lead to a proteoglycan
Fig. 5 Slc10a7−/− mice exhibit long-bone macro- and microstructure defects. a Alizarin red/Alcian blue staining of newborn femurs and measurement of
newborn femur length and femur length/width ratio. Scale bars= 1 mm. n= 8 (Slc10a7+/+), n= 9 (Slc10a7+/−) and n= 10 (Slc10a7−/−). b Three-
dimensional reconstruction of μCT analysis of 8-week-old mouse femurs and measurement of 8-week-old femur length and femur length/width ratio.
Scale bars= 1 mm. Panels (a) and (b) demonstrate that Slc10a7−/− femurs, both at birth and at 8 weeks, are shorter and thicker, and exhibit morphological
defects. c Three-dimensional μCT of sections of 8-week-old distal femur metaphyses from Slc10a7+/+ and Slc10a7−/− mice. Scale bars= 1 mm. Graphs
show trabecular and cortical bone volume (BV/TV) and bone mineral density (BMD). n= 7 (Slc10a7+/+), n= 7 (Slc10a7+/−) and n= 6 Slc10a7−/−). d
Safranin O staining of the distal femur epiphysis of newborn Slc10a7+/+ and Slc10a7−/− mice. Right panels show higher magniﬁcation of the growth plate.
Scale bars= 250 μm. e Masson’s Trichome staining of distal femur epiphysis of newborn Slc10a7+/+ and Slc10a7−/− mice. Scale bars= 250 μm. HZ,
hypertrophic zone; PHZ, prehypertrophic zone; PZ, proliferative zone; RZ, resting zone. Images are representative of n= 10 and n= 5 per group for Safranin
O and Masson’s Trichome staining, respectively. Data are expressed as mean ± SD. NS, nonsigniﬁcant; *p≤ 0.05; **p≤ 0.0.1; ****p≤ 0.0001 (two-tailed
t-test)
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synthesis defect and, more speciﬁcally, to decreased HS content.
HS biosynthesis is initiated by the addition of N-acet-
ylglucosamine (GlcNac), catalysed by EXTL2 and EXTL3
enzymes. EXT1 and EXT2 are then responsible for the chain
elongation by adding alternating glucuronic acid and GlcNac
sugar subunits. HS ﬁnal structure and speciﬁc function is ﬁnally
modulated by epimerisation, sulfation and deacetylation25. The
unchanged HS chain length and sulfation pattern in the Slc10a7
−/− deﬁcient mouse cartilage indicates that the decreased HS
levels are associated to a reduced number of HS chains. These
ﬁndings suggest an impairment of the initial step of HS chain
synthesis. This signiﬁcant reduction in HS, while the total GAG
concentration was not altered, could be explained by compen-
satory CS synthesis, as observed in Ext1−/− ES cells26 and
EXTL3-deﬁcient patients27. In addition to altered proteoglycan
synthesis, an abnormal electrophoretic pattern for two N-glyco-
proteins, oromucosoid and haptoglobin, was observed, suggesting
that in addition to GAG synthesis SLC10A7 deﬁciency may also
affect other types of glycosylation28.
Very interestingly, SLC10A7 deﬁciency was also responsible for
an increased Ca2+ intracellular intake in skin ﬁbroblasts, con-
ﬁrming a role for SLC10A7 in intracellular calcium homoeostasis,
as previously suggested by studies in yeast homologues. This
deregulation of Ca2+ homoeostasis due to SLC10A7 deﬁciency is
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Fig. 6 SLC10A7 deﬁciency leads to defective GAG and enhanced Ca2+ intake. a, b Total sulfated GAGs and heparan sulfates (HS) were quantiﬁed according
to the DMMB procedure in extracts of SLC10A7-deﬁcient patient ﬁbroblasts and control ﬁbroblasts (n= 3) (a) or in cartilage extracts from 10-day-old
Slc10a7−/− or Slc10a7+/+ mice (n= 5) (b). Proportions of HS are expressed as a percentage of total sulfated GAGs (% HS). c Immunohistoﬂuorescence
for HS (red) or CS (red) counterstained with DAPI (blue) on distal femurs of newborn Slc10a7+/+ and Slc10a7−/−mice (n= 5 mice). Arrows indicate more
intense CS staining at the close proximity of chondrocytes. Scale bars= 100 μm. Graphs show red ﬂuorescent signal intensity in the growth plate for each
marker. a.u., arbitrary unit. Data are expressed as mean ± SD. NS, nonsigniﬁcant; **p≤ 0.01 (two-tailed t-test). d A representative recording of intracellular
free Ca2+ in SLC10A7-deﬁcient patients ﬁbroblasts and control ﬁbroblasts (n= 3). Fibroblasts were loaded with Fluo-4-AM and preincubated in calcium-
free buffer for 30min before addition of 20 μM CaCl2. Data are presented as mean ± SEM, *p≤ 0.05; **p≤ 0.0.1 (two-tailed t-test)
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most likely responsible for defects in GAG synthesis and
glycosylation.
Bone formation and development, through endochondral
ossiﬁcation, are governed by gradients of signalling molecules,
including Indian hedgehog (Ihh), parathyroid hormone-related
protein, ﬁbroblast growth factors, Wnt proteins and bone mor-
phogenic proteins29. Proteoglycans, such as CS proteoglycans
(CSPGs) and HS proteoglycans (HSPGs), are important mod-
ulators of signalling modulator gradients. Several studies have
shown that CSPGs and HSPGs have different effects, and in some
cases opposite effects, on the regulation of growth factor-
mediated signal transductions, as demonstrated, e.g., for Ihh
diffusion30,31. Thus, an alteration of the CSPGs/HSPGs ratio, as
observed in our study, could affect the signalling pathways reg-
ulating chondrocyte proliferation and differentiation, explaining
the growth plate disorganization observed in Slc10a7−/− mice.
Although phenotypic similarities between the pug mutant, i.e.,
Xylt1-deﬁcient mice, and our Slc10a7−/− mouse model suggest
that the underlying mechanisms leading to growth defects are
similar, i.e., premature chondrocyte maturation and early ossiﬁ-
cation32, further analyses of growth factor signalling pathways are
necessary to fully understand the pathogenesis of the skeletal
dysplasia induced by SLC10A7 deﬁciency.
Finally, all individuals with SLC10A7 mutations presented with
a hypomineralized amelogenesis imperfecta. Analyses of Slc10a7
−/− mouse teeth demonstrated a defective outermost enamel
layer and less clearly deﬁned enamel rods, whereas the global
enamel thickness was not affected, suggesting alterations in
enamel maturation and/or mineralization. Mature enamel is the
hardest and the most mineralized tissue in the human body.
Amelogenesis, or enamel formation, is orchestrated by amelo-
blasts, which are responsible for the synthesis of the protein
matrix scaffold and the calcium hydroxyapatite crystal deposi-
tion33. Although no proteoglycan defects have been associated
with amelogenesis imperfecta in humans, several mouse studies
have demonstrated the implication of proteoglycans, such as
perlecan and decorin, in enamel formation34,35. As mentioned
above, amelogenesis imperfecta seems to be a phenotypic feature
speciﬁc to SLC10A7 deﬁciency within the group of chon-
drodysplasias with multiple dislocations, suggesting that amelo-
genesis imperfecta is not due to a defect in proteoglycan synthesis
but to a different function of SLC10A7. It can rather be explained
by a role of SLC10A7 in Ca2+ inﬂux homoeostasis suggested by
the increased Ca2+ intracellular intake in SLC10A7-deﬁcient
patients ﬁbroblasts. Indeed, during the maturation stage, which
seems to be affected by SLC10A7 deﬁciency, an increase in active
transport of calcium by the ameloblasts in the enamel occurs.
Furthermore, mutations in genes encoding for Ca2+ transporters,
such as SLC24A4, have been identiﬁed in patients with amelo-
genesis imperfecta36.
In conclusion, our functional work-up of SLC10A7 has iden-
tiﬁed a new gene responsible for skeletal dysplasia and amelo-
genesis imperfecta, illustrating the complexity of GAG synthesis
and the putative role of Ca2+ homoeostasis in this process, thus
opening new possibilities for the development of therapeutic
approaches by correcting the defective Ca2+ homoeostasis in the
Golgi.
Methods
Affected individuals. The affected individuals selected for this study fulﬁlled the
diagnostic criteria for chondrodysplasia with multiple dislocations, namely short
stature and dislocations of large joints. GeneMatcher37 was used to identify other
physicians caring for patients with variants in SLC10A7.
Samples. The studies were approved by the ethics committees of the Necker
Hospital (Paris) and Julius Maximilians University Würzburg. Parents or guardians
provided written informed consent for the biochemical and genetic analysis and
the publication of photographs and clinical data. The authors afﬁrm that human
research participants provided informed consent for publication of the images in
Fig. 1. DNA was extracted from venous blood using QIAamp DNA blood Maxi kit
(QIAGEN). Fibroblast cultures were established from skin biopsies.
Exome sequencing. Exome capture was performed at the genomic platform of the
IMAGINE Institute (Paris, France) with the SureSelect Human All Exon kit
(Agilent Technologies) for the three Turkish patients, at the University Medical
Center Utrecht and University Medical Center Groningen for the two Dutch
patients and at the Institute of Human Genetics at the Julius Maximilians Uni-
versity Würzburg for the Iranian patients. Agilent SureSelect Human All Exon (V4)
libraries were prepared from 3 μg of genomic DNA sheared with ultrasonicator
(Covaris) as recommended by the manufacturer.
Barcoded exome libraries were pooled and sequenced using a HiSeq2500
(Illumina), generating paired-end reads. After demultiplexing, sequences were
mapped to the human genome reference (NCBI build37/hg 19 version) with
Burrows–Wheeler Aligner38. The mean depth of coverage obtained for each sample
was ≥ × 80 with 95% of the exome covered at least × 15. Variant calling was carried
out with the Genome Analysis Toolkit (GATK)39, Sequence Alignment/Map
tools40 and Picard Tools. Single-nucleotide variants were called with GATK
Uniﬁed Genotyper, whereas indel calls were made with the GATK
IndelGenotyper_v2. All variants with a read coverage ≤ × 2 and a Phred-scaled
quality of ≤ 20 were ﬁltered out. Variants were annotated and ﬁltered using an in-
house annotation software system (Polyweb, unpublished).
The analyses focused on non-synonymous variants, splice variants, and coding
indels. Variant pathogenicity was evaluated using the prediction algorithms SIFT
(cutoff ≤ 0.05), PolyPhen-2 (HumVar scores, cutoff ≥ 0.447) and Mutation Taster
(cutoff: qualitative prediction as pathogenic). The variant frequency in control
datasets was assessed, including the ExAC database, dbSNP129, the 1000 Genomes
project, ClinVar, HGMD and in-house exome data. All variants were conﬁrmed by
Sanger sequencing and segregation was veriﬁed.
Sequencing analysis of SLC10A7. The exons and exon–intron boundaries of
SLC10A7 were ampliﬁed with speciﬁc primers (Supplementary Table 1). Ampliﬁ-
cation products were puriﬁed by ExoSapIT (Amersham) and directly sequenced
with the Big Dye Terminator Cycle Sequencing Ready Reaction kit v1.1 on an
automatic sequencer (3500XL and 3130XL; PE Applied Biosystems). Sequence
analyses were performed with the analysis software, Sequencing 6 (Applied Bio-
systems) and Gensearch (PhenoSystems SA).
SLC10A7 expression plasmids. Skin primary ﬁbroblasts (control and case 1 and
3) were cultured in RPMI medium supplemented with 10% fetal calf serum. Total
RNAs from ﬁbroblast monolayers were extracted using the RNeasy Mini kit
(Qiagen) according to the manufacturer’s instructions. SLC10A7 cDNA was
ampliﬁed after reverse transcription of RNA using the forward primer 5′-AAG-
GATCCCCCTAACAAATATGAGGCTGCTGG-3′ (BamHI restriction site
underlined) and the reverse primer 5′-AACTCGAGGTA-
TACTGTCGGCCTTGTCAGCTT-3′ (XhoI restriction site underlined). The
resulting amplicons were cloned into pcDNA™3.1/Myc-His A+ (Invitrogen) to
generate proteins with an in-frame Myc-His Tag and then sequenced to verify the
correct insertion.
Recombinant protein expression. HEK293F cells, COS-1 cells and MG63 cells
(ATCC) were cultured in Dulbecco’s modiﬁed Eagle’s mmedium supplemented
with 10% fetal bovine serum (FBS). Transfections were performed on cells in 24-
well plates or in 8-chamber labtek slides (ThermoFisher Scientiﬁc) using jet-
PRIME® transfection reagent (Polyplus Transfection) according to the manu-
facturer’s instructions.
For western blotting, cells in 24-well plates were collected 48 h after transfection
and lysed in denaturation buffer. Polyacrylamide gel electrophoresis, transfer and
immunoblotting were performed according to standard protocols using
monoclonal anti-myc (9E10; 1/1000; Santa Cruz Biotechnologies) or monoclonal
anti-actin (clone C4; 1/5000; Millipore) primary antibodies and goat anti-mouse
HRP-conjugated secondary antibody (1/2000; Novex, Life Technologies, catalogue
number A16066).
For immunoﬂuorescence, cells in 8-chamber slides were ﬁxed 48 h after
transfection with 4% paraformaldehyde (PFA) at room temperature for 30 min.
The washed cell layer was incubated sequentially in phosphate-buffered saline
(PBS) containing 1% bovine serum albumin (BSA) for 30 min, mouse monoclonal
anti-myc antibody for 1 h and Alexa Fluor 594 goat anti-mouse IgG (1/200; Life
Technologies, catalogue number A11005) for 1 h. After mounting in Prolong gold
antifade mountant with DAPI (Molecular Probes, Life Technologies) cells were
observed with an Axioplan2 imaging microscope (Zeiss).
In situ hybridization. Probes for SLC10A7 and Slc10a7 corresponded to nucleo-
tides 46-948 of GenBank accession NM_001029998.5 and nucleotides 429-717 of
GenBank accession NM_001009981.2, respectively. Synthetic cDNAs (Euroﬁns
Genomics) were used to generate antisense and sense cRNA probes using a SP6/T7
DIG RNA labelling kit (Roche) and digoxigenin-11-UTP (Roche) according to the
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manufacturer's speciﬁcations. Parafﬁn sections of paraformaldehyde-ﬁxed human
fetuses at 6 and 7 weeks of gestation (Carnegie stages 16 and 19, respectively;
obtained with institutional review board approval), murine wild-type embryos at
embryonic age E12.5, E14.5 and E16.5, and tissues from wild-type newborn and 10-
day-old mice were deparafﬁnized. These sections were treated with 20 μg/ml
Proteinase K for 8 min at 37 °C and postﬁxed with 4% PFA for 12 min. After
washing in PBS and 2 × Saline Sodium Citrate Buffer (SSC), they were acetylated in
0.25% acetic anhydride in 0.1 M triethanolamine for 10 min. The sections were
hybridised to 5 μg/ml DIG-11-UTP-labelled SLC10A7 or Slc10a7 cRNA probes in
hybridization buffer (50% formamide, 10 mM Tris-HCl (pH 7.6), 1 mM EDTA
(pH 8), 600 mM NaCl, 10% dextran sulfate sodium salt, 1 mg/ml Yeast tRNA and
1 × Denhardt’s solution) overnight at 70 °C. After hybridization, each slide was
washed in 2 × SSC containing 50% formamide at 65 °C for 30 min. Each slide was
treated with 20 μg/ml RNAse A in TNE (10 mM Tris-HCl (pH 7.6), 1 mM EDTA,
50 mM NaCl) at 37 °C for 30 min and washed in TNE. Subsequently, the slides
were washed twice with 2 × SSC and 0.1 × SSC at room temperature for 15 min
each [41]. After staining with 5-bromo-4-chloro-3'-indoylphosphate p-toluidine
salt and nitroblue tetrazolium chloride in the dark (Roche) according to manu-
facturer’s recommendations, slides were scanned using a Nanozoomer 2.0 scanner
(Hamamatsu) and visualized using NDPviewer (Hamamatsu).
GAG assays. For analysis of GAG content in primary ﬁbroblasts from patients and
controls, 7 × 106 cells at conﬂuence in 75 cm2 ﬂasks were washed twice in PBS
before treatment with trypsin. Then, RPMI medium was added and cells were
centrifuged at 2000 × g for 5 min and suspended in 1600 µl of extraction buffer (50
mM Tris-HCl pH 7.9, 10 mM NaCl, 3 mM MgCl2 and 1% Triton X-100). After
incubation for 15 min at 4 °C, 10 μl was removed for protein quantiﬁcation with
BCA Assay (Thermoﬁsher). Proteins were digested by proteinase K treatment (200
µg/mL) at 56 °C overnight followed by 30 min at 90 °C for inactivation of protei-
nase K. After cooling, 7.5 U of DNAse I (QIAGEN) was added and the samples
incubated overnight at 37 °C. To ensure complete DNA elimination, samples were
centrifuged 10 min at 10,000 × g in Nanosep MF 0.2 µm tubes from Pall Cor-
poration (France). To complete the separation of protein from GAGs, NaCl was
added at a ﬁnal concentration of 4 M and samples were vortexed for 30 min.
Trichloroacetic acid (10% ﬁnal concentration) was added at 4 °C and samples were
stored at this temperature for 15 min. The samples were then centrifuged at
10,000 × g for 10 min and the pellet discarded. Trichloroacetic acid (TCA) was
eliminated by chloroform extraction followed by serial dialyses of the aqueous
phase against a Tris buffer (50 mM Tris-HCl, 50 mM sodium acetate and 2 mM
calcium chloride, pH 8) and water. Samples were lyophilized then dissolved in pure
water or in glycanase digestion buffer (100 mM sodium acetate, 10 mM calcium
chloride, pH 7).
For extraction of GAGs from mouse tissues, cartilages and skeletal muscle from
10-day-old mice were weighed then suspended in 2 ml of extraction buffer and
ﬁnally their GAGs were extracted as detailed above for cells.
Following extraction, sulfated GAGs were quantiﬁed according to the protocol
described by Barbosa et al.42 with slight modiﬁcations. Total sulfated GAGs,
amount of HS after chondroitinase treatment (Sigma, 10 U/ml) and of CS after
heparitinase I/II/II (0.25 U/ml each) treatment were quantiﬁed according to the
DMMB (1-9 dimethyl-methylene blue) assay. A calibration curve, constructed with
known amounts of a CS-A standard ranging from 0.25 to 3.0 µg, was included in
every assay. For the cells, total GAGs quantiﬁcation is expressed in function of their
protein content. For mice cartilage, total GAGs quantiﬁcation is expressed in
function of their dried weight. HS and CS are expressed as percentage of total
GAGs. HPLC analysis of HS and GAG length were performed as previously
descrided43,44.
Ca2+ imaging. Human skin ﬁbroblasts were plated at 15 × 103 cells/cm2 in μ-slide
8-well glass bottom (Ibidi) in RPMI media containing 10% FBS. After 24 h, the
media was replaced with serum-free fresh media. After 2 h of serum starvation, the
cells were incubated in buffer containing ﬂuo-4 dye (2 µM) for 30 min. Cells were
washed three times with Ca2+ -free buffer and then kept in Ca2+-free buffer
(140 mM NaCl, 4 mM KCl, 1 mM MgCl2, 25 mM glucose and 10 mM HEPES, pH
7.4). Under ﬂuorescent microscopy (Nikon Instruments Eclipse Ti Inverted
Microscopes, NIS-Elements Microscope Imaging software), in Ca2+-free buffer,
CaCl2 (20 mM) was then added extracellularly to facilitate Ca2+ inﬂux. Peak
ﬂuorescent intensities following CaCl2 were captured and average values from at
least two sets of cells per patient or control were obtained for analysis. Data were
analysed as the percentage of ﬂuorescence intensity before Cacl2 for each cell.
Glycoprotein electrophoretic proﬁle assay. For analysis of glycoproteins from
blood spots on Guthrie cards, one circular punched spot was ﬁrst eluted in 100 μl of
distilled water. Blood eluate was ﬁvefold diluted in distilled water. SDS-PAGE was
carried out as described by the manufacturer (Life Technologies) using 4–12%
NuPAGE Bis-Tris gels and 2 dimensional gel electrophoresis (2-DE) was carried
out on 10 μl of blood eluate as described by the manufacturer (Life Technologies)
using ZOOM Strip pH 4–7 for the ﬁrst dimension and 4–12% NuPAGE Bis-Tris
gels for the second dimension. In both cases, separated proteins were transferred to
nitrocellulose (100 Volts, 1 h) and protein glycoforms haptoglobin (Hpt) and
orosomucoid (oroso) were identiﬁed using the following rabbit primary antibodies:
anti-haptoglobin (Dako, catalogue number A0030; 1/5000 in Tris-Tween-Buffer-
Saline); anti-orosomucoid (Dako, catalogue number Q0326; 1/2000 in Tris-Tween-
Buffer-Saline (TTBS); anti-transferrin (Siemens, catalogue number OSAX15; 1/
4000 in TTBS) and anti-α-anti-trypsin (Siemens, catalogue number OSA209; 1/
10,000 in TTBS). HRP-linked anti-rabbit IgG (GE Healthcare, catalogue number
NA934V; 1/5000 in TTBS) was used as secondary antibody. Images were acquired
using a Chemidoc XRS camera system from Bio-Rad.
Generation of Slc10a7−/− mice. All procedures were performed in accordance
with the guidelines for animal care of French Animal Care and Use Committee.
Slc10a7tm1a(EUCOMM)Hmgu ES cells (MGI:1924025) from the EuMMCR were
injected into blastocysts from grey C57Bl/6N mice by PolyGene AG. The resulting
chimerae were bred with C57Bl/6N mice to obtain Slc10a7tm1a(EUCOMM)Hmgu/+
mice (referred to as Slc10a7+/−). The mice were genotyped using the following
primers: 5′-CCGCTTCCTCGTGCTTTAGGTA-3′ and 5′-
AACCTCTACAGATGTGATATGGCTG-3′ for transgenic allele ampliﬁcation,
and 5′-GAATCCAGTACAGGAGAGCCACAT-3′ and 5′-
TAGAGACCAGGAATTCTGCTAGACA-3′ for wild-type allele ampliﬁcation. For
timed pregnancies, the date of vaginal plug was designated E (embryonic age) 0.5.
For all analyses of Slc10a7+/− and Slc10a7−/−mice, wild-type littermates were used
as controls, and both male and female were used at birth, 10 days of age and
8 weeks of age, as indicated.
Skeletal staining. Newborn skeletons were skinned, ﬁxed in 95% ethanol, stained
with Alcian Blue and Alizarin Red, cleared by KOH treatment and stored in
glycerol according to standard protocols.
Images were captured with an Olympus SZX12 stereo-microscope. Bone sizes
were measured using ImageJ software.
X-rays and μCT. Whole mouse skeletons were radiographed using a Faxitron
(MX-20). For μCT analyses adult animals were euthanized and femurs and heads
were isolated, stripped of soft tissue and stored in 70% ethanol. Three-dimensional
microarchitecture of the distal femur was evaluated using a high-resolution Sky-
scan1076 microtomographic imaging system (Skyscan, Belgium). Images were
acquired at 80 KeV, 100 μA, no ﬁlter. Three-dimensional reconstructions were
generated using NRecon software (Skyscan). Trabecular and cortical measurements
were obtained using CTan software (Skyscan) on a set of sections located within
the secondary spongiosa under the growth plate and under the secondary spon-
giosa, respectively. The measured volume was chosen to be proportional to the
femur length.
Avizo software (FEI Visualization Sciences Group, Burlington, MA) was used
for three-dimensional visualization of heads and for mandible, incisor and molars
selection and volume quantiﬁcation.
Scanning electron microscopy analysis of incisor enamel. Mandibles from 8-
week-old Slc10a7−/− and Slc10a7+/+ mice (three of each genotype) were dissected
out and stored in 70% ethanol. Incisors were cut along the frontal axis at the level
of bone emergence using a rotating diamond wheel and optically controlled
monitoring. Previous microscanner analysis was used to validate the cutting axis
(perpendicular to incisor axis), in order to analyse the buccal part of the incisor.
Sample surfaces were polished with sandpaper of successively decreasing grits.
Conditioning of the enamel surface was achieved by etching with 37% phosphoric
acid for 30 s and carefully drying. Each sample was observed with a scanning
electron microscope (TM3030, table top Microscope, Hitachi) at 10 kV. Incisor
morphology was used as a criterion for calibration of section planes, based on
established μCT-landmarks.
Histology and immunohistochemistry. Newborn femurs were ﬁxed in 4% par-
aformaldehyde, decalciﬁed with 0.4 M EDTA before parafﬁn embedding and 5 μm
sections were used for Safranin O and Masson’s trichrome staining or
immunoﬂuorescence.
For immunoﬂuorescence, sections were subjected to digestion with 0.5 U/ml
chondroitinase ABC (Sigma-Aldrich) for 2 h at 37 °C and, after blocking with 1%
BSA, were incubated with anti-HS (1/100, Amsbio, clone F58-10E4, catalogue
number 370255-1) and anti-CS (1/200, Amsbio, clone 2B6, catalogue number
270432-CS) antibodies. Alexa ﬂuor 594 goat anti-mouse was used as secondary
antibody and slides were mounted in Prolong Gold Antifade with DAPI mounting
medium (1/200; Life Technologies, catalogue number A11005) and scanned using a
Nanozoomer 2.0 (Hamamatsu). Speciﬁc signal intensity was measured with ImageJ
software, selecting equivalent areas of the growth plate in each group.
Statistics. Statistical analyses were performed using GraphPad PRISM. All values
are shown as mean ± SD. Statistical differences between two groups were analysed
with a two-tailed Student’s t-test, assuming a normal distribution. A p-value of <
0.05 was considered statistically signiﬁcant.
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PolyPhen-2, see http://genetics.bwh.harvard.edu/pph2. For SIFT, see http://www.
sift.jcvi.org. For UCSC Genome Browser, see http://www.genome.ucsc.edu. For
EUCOMM, see http://www.mousephenotype.org/data/genes/.
Data availability. The authors declare that all the data supporting the ﬁndings of
this study are available within the paper and its Supplementary Information ﬁles.
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